Wall Street Associates’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Wall Street Associates’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-23,300	Closed	-$318K	–	236
2016 Q1	$318K	Hold	23,300	–	–	0.13%	173
2015 Q4	$442K	Hold	23,300	–	–	0.12%	216
2015 Q3	$437K	Sell	23,300 -252,200	-92%	-$4.29M	0.08%	232
2015 Q2	$4.1M	Sell	275,500 -10,600	-4%	-$161K	0.39%	89
2015 Q1	$4.33M	Sell	286,100 -7,700	-3%	-$107K	0.41%	88
2014 Q4	$3.91M	Hold	293,800	–	–	0.38%	91
2014 Q3	$3.71M	Sell	293,800 -29,800	-9%	-$289K	0.38%	94
2014 Q2	$3.27M	Buy	323,600 +2,400	+0.7%	+$23.2K	0.28%	118
2014 Q1	$4.32M	Buy	+321,200	New	+$4.53M	0.35%	101

Other funds holding CNCE

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

SAM

Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Wall Street Associates's CNCE Position: Q2 2016 in Review

Wall Street Associates sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q2 2016, closing a stake of 23,300 shares — an estimated $318K sold.

Wall Street Associates first reported a position in CNCE in Q1 2014 and held it in 9 quarters. The position peaked at $4.33M in Q1 2015. 97 funds tracked by Wall St. Rank hold CNCE as of Q2 2016.

Wall Street Associates reported no remaining Concert Pharmaceuticals, Inc. position as of Q2 2016 after selling out during the quarter.
Wall Street Associates sold 23,300 Concert Pharmaceuticals, Inc. shares in Q2 2016, an estimated $318K.
Wall Street Associates first reported a position in Concert Pharmaceuticals, Inc. in Q1 2014 and held it in 9 quarters.
Wall Street Associates's Concert Pharmaceuticals, Inc. position peaked at $4.33M in Q1 2015.
97 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q2 2016.

Based on Wall Street Associates's 13F filing for Q2 2016, filed 12 Aug 2016.